Teikoku Pharma USA Inc.
Division of Teikoku Seiyaku Co. Ltd.
Latest From Teikoku Pharma USA Inc.
Market Intel: Pain Is Biggest Market For Transdermal Drug Delivery But Not A Patch Over Neuro For Growth
The growing aging population and rising obesity rates are paving the way for patch-based drug delivery systems to treat such common age-related diseases as Alzheimer's and Parkinson's, hormonal deficiencies, heart disease, as well as for managing acute and chronic pain patients. According to a new report by Meddevicetracker, the global market for transdermal patch products will reach $8.1bn by 2021, a CAGR of 2.9% from 2016. In this feature, we'll take a closer look at the overall market and the key players in the individual segments in this overall market. We'll take a deep dive into the neurological disorders segment, which is expected to see the biggest growth in the overall segment. We'll also feature physician specialty surveys outlining the pros and cons of using patch-based systems.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
In addition to settling with Endo, FTC refiles charges against Watson (now Teva), Allergan and Impax involving Lidoderm and Opana ER patent litigation settlements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.
- Topical Delivery
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Teikoku Seiyaku Co. Ltd.
- Senior Management
Ichiro (Paul) Mori, Pres. & CEO
Atsumu Matsushita, EVP, CFO
Jutaro Shudo, PhD, SVP, CSO
Francisco Bejar, VP, Licensing & Strategic Alliances
- Contact Info
Teikoku Pharma USA Inc.
Phone: (408) 501-1800
1718 Ringwood Ave.
San Jose, CA 95131
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.